Pharvaris N.V.
Forward trial catalysts linked to PHVS
CSA tracks 1 forward catalyst for Pharvaris N.V. across 1 asset, spanning Phase 2/3. The nearest is a readout expected Jun 2027 (month precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Hereditary Angioedema, Hereditary Angioedema (HAE), Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH).
PHVS in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Pharvaris N.V. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
4 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| deucrictibant | NCT06669754 | Phase 3 | Active, not recruiting | 2026-08 | Experimental | Pharvaris Netherlands B.V. | Hereditary Angioedema (HAE) |
| deucrictibant | NCT05396105 catalyst | Phase 2/3 | Enrolling by invitation | 2027-06 | Experimental | Pharvaris Netherlands B.V. | Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Heredi… |
| deucrictibant | NCT07266805 | Phase 3 | Recruiting | 2027-06 | Experimental | Pharvaris Netherlands B.V. | Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) |
| deucrictibant | NCT06679881 | Phase 3 | Enrolling by invitation | 2028-12 | Experimental | Pharvaris Netherlands B.V. | Hereditary Angioedema (HAE) |
Every trial the CSA sample links to PHVS's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →